首页> 外文期刊>RSC Advances >Design, synthesis and biological evaluation of 2-amino-N-(2-aminophenyl)thiazole-5-carboxamide derivatives as novel Bcr-Abl and histone deacetylase dual inhibitors
【24h】

Design, synthesis and biological evaluation of 2-amino-N-(2-aminophenyl)thiazole-5-carboxamide derivatives as novel Bcr-Abl and histone deacetylase dual inhibitors

机译:2-氨基-N-(2-氨基苯基)噻唑-5-甲酰胺衍生物作为新型BCR-ABL和组蛋白脱乙酰化酶双抑制剂的设计,合成和生物学评价

获取原文
           

摘要

In recent studies, combinations of histone deacetylase (HDAC) inhibitors with kinase inhibitor showed additive and synergistic effects. Herein we present a novel design approach for cancer drug development by combination of breakpoint cluster Abl (Bcr-Abl) and HDAC inhibitory activity, two independent pharmacological activities, in one molecule. The designed compounds were synthesized and tested, showing inhibitory activity against Bcr-Abl and HDAC1. The representative dual Bcr-Abl/HDAC inhibitors, compounds 6a and 6m , showed potent antiproliferative activities against human leukemia cell line K562 and prostate cancer cell line DU145 in cellular assays. This work may lay the foundation for developing dual Bcr-Abl/HDAC inhibitors as potential anticancer therapeutics.
机译:在最近的研究中,具有激酶抑制剂的组蛋白脱乙酰酶(HDAC)抑制剂的组合显示添加剂和协同作用。在此,我们通过断点聚类ABL(BCR-ABL)和HDAC抑制活性,两个独立的药理学活性,在一个分子中提出了一种新的癌症药物开发的设计方法。合成设计的化合物并测试,显示针对BCR-ABL和HDAC1的抑制活性。代表性的双BCR-ABL / HDAC抑制剂,化合物6a和6m,显示出对人白血病细胞系K562和前列腺癌细胞系DU145的有效的抗增殖活动。这项工作可以为开发双BCR-ABL / HDAC抑制剂作为潜在的抗癌治疗方法奠定基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号